0HF3.L
Cencora
Q3 2025 Report
Cencora (0HF3.L) Q3 2025 Financial Results: Robust Growth Amidst Industry Challenges...
Read full report
Executive Summary
In Q4 2024, Cencora (0HF3.L) reported significant year-over-year revenue growth of 14.69%, reaching $79.05 billion, largely driven by increased demand in its healthcare solutions segments. However, profit margins declined sharply, with net income plummeting by 99.04% to just $3.38 million. This considerable drop in profitability is attributed to rising operational costs and strategic investments that have yet to yield measurable outputs. Despite challenges in maintaining profitability, the company remains well positioned due to its extensive distribution network and a growing portfolio of essential healthcare products, particularly as demand from healthcare systems continues to grow.
Key Performance Indicators
Revenue
79.05B
QoQ: 6.48% | YoY:14.69%
Gross Profit
2.49B
3.15% margin
QoQ: 19.45% | YoY:10.60%
Operating Income
126.64M
QoQ: -82.00% | YoY:-73.45%
Net Income
3.38M
QoQ: -99.30% | YoY:-99.04%
EPS
0.02
QoQ: -99.18% | YoY:-98.85%
Revenue Trend
Margin Analysis
Key Insights
- **Revenue**: $79.05 billion (+14.69% YoY, +6.48% QoQ)
- **Gross Profit**: $2.49 billion (+10.60% YoY, +19.45% QoQ)
- **Operating Income**: $126.64 million (-73.45% YoY, -82.00% QoQ)
- **Net Income**: $3.38 million (-99.04% YoY, -99.30% QoQ)
- **EPS**: $0.02 (-98.85% YoY, -99.18% QoQ)